Zoetis, Inc. Class A Stock

$155.65

0.45% yesterday

NYSE, Jul 14, 10:00 pm CET

ISIN

US98978V1035

Symbol

ZTS

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Zoetis, Inc. Class A Stock price

$155.65

+15.25 10.86% 5Y

NYSE, Closing price Mon, Jul 14 2025

+0.69 0.45%

ISIN

US98978V1035

Symbol

ZTS

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$69.0b

Enterprise Value

$73.8b

Net debt

$4.9b

Cash

$1.7b

Shares outstanding

446.0m

Valuation (TTM | estimate)

P/E

27.6 | 24.7

P/S

7.4 | 7.2

EV/Sales

8.0 | 7.7

EV/FCF

32.4

P/B

14.8

Dividends

DPS

$1.80

Yield 1Y | 5Y

1.2% | 0.8%

Growth 1Y | 5Y

15.4% | 21.0%

Payout 1Y | 3Y

32.8% | 31.3%

Increased

12 Years

Financials (TTM | estimate)

Revenue

$9.3b | $9.6b

EBITDA

$3.6b | $4.2b

EBIT

$3.4b | $3.7b

Net Income

$2.5b | $2.8b

Free Cash Flow

$2.3b

Growth (TTM | estimate)

Revenue

6.3% | 3.5%

EBITDA

8.8% | 17.6%

EBIT

9.6% | 8.8%

Net Income

5.3% | 12.8%

Free Cash Flow

30.3%

Financial Health

Equity Ratio

33.5%

Return on Equity

52.1%

ROCE

32.2%

ROIC

23.9%

Debt/Equity

1.4

EPS

$5.6

FCF per Share

$5.1

Short interest

2.0%

Employees

14k

Rev per Employee

$670.0k

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

Zoetis, Inc. Class A Stock Analysis

Unlock Scores for Free

??

24 Analysts have issued a Zoetis, Inc. Class A forecast:

18x Buy

75%

6x Hold

25%

More details on Analyst Estimates Including Price Targets

24 Analysts have issued a Zoetis, Inc. Class A forecast:

Buy

75%

Hold

25%

Analyst Estimates with Stock Price Targets

Financial data from Zoetis, Inc. Class A

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	9,286 9,286	6% 6% 100%
- Direct Costs	2,695 2,695	3% 3% 29%
Gross Profit	6,591 6,591	8% 8% 71%
- Selling and Administrative Expenses	2,334 2,334	6% 6% 25%
- Research and Development Expense	681 681	7% 7% 7%
EBITDA	3,582 3,582	9% 9% 39%
- Depreciation and Amortization	136 136	9% 9% 1%
EBIT (Operating Income) EBIT	3,446 3,446	10% 10% 37%
Net Profit	2,518 2,518	5% 5% 27%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Zoetis, Inc. Class A Stock News

Positive

The Motley Fool

●

8 days ago

3 Magnificent S&P 500 Dividend Stocks Down 19% to 26%: Is It Time to Buy the Dip?

I am an adherent to the Gardner-Kretzmann Continuum's strategy of owning at least one stock for each year of your age. Because of this notion, I have 37 "core" holdings that I try to add to consistently over time.

Positive

The Motley Fool

●

9 days ago

2 Dividend Growth Stocks to Buy and Hold Forever

For investors focused on the long game, there is little reason to sell -- at least, so long as a company generates solid returns through consistently improving financial results, regularly increases its dividend (if it pays one), and maintains strong growth prospects. Although it's sometimes difficult to find corporations that can do all that over long periods, stocks of this caliber do exist.

Positive

Seeking Alpha

●

12 days ago

Zoetis: Growth To Continue Thanks To Companion Animals

Zoetis remains a compelling long-term investment, driven by strong growth in companion animal products and a resilient pet care market. Despite recent underperformance and valuation concerns, Zoetis's leadership, scale, and innovation position it well against new competitors. Financials show steady revenue, profit, and dividend growth, with management raising full-year guidance and focusing on ...

More Zoetis, Inc. Class A News

Company Profile

Zoetis, Inc. discovers, develops and manufactures a portfolio of animal health medicines and vaccines. The company operates through the following segments: United States &International. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The company provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals. Zoetis was founded in 1952 and is headquartered in Parsippany, NJ.

Head office	United States
CEO	Kristin Peck
Employees	13,800
Founded	1952
Website	www.zoetis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now